scholarly journals Smilax aristolochiifolia Root Extract and Its Compounds Chlorogenic Acid and Astilbin Inhibit the Activity of α-Amylase and α-Glucosidase Enzymes

2018 ◽  
Vol 2018 ◽  
pp. 1-12 ◽  
Author(s):  
Viridiana Candelaria Pérez-Nájera ◽  
Janet Alejandra Gutiérrez-Uribe ◽  
Marilena Antunes-Ricardo ◽  
Sergio Hidalgo-Figueroa ◽  
Carmen Lizette Del-Toro-Sánchez ◽  
...  
Keyword(s):  
Chlorogenic Acid ◽  
Metabolic Effects ◽  
Root Extract ◽  
Enzymatic Assays ◽  
Glucosidase Activity ◽  
Hydrolyzing Enzymes ◽  
Hydroethanolic Extract ◽  
Fast Centrifugal Partition Chromatography ◽  
Main Strategy

Regulating activities of α-amylase and α-glucosidase through the use of specific inhibitors is a main strategy for controlling type 2 diabetes. Smilax aristolochiifolia root decoctions are traditionally used in Mexico as hypoglycemic and for weight loss, but the active principles and mechanisms underlying such putative metabolic effects are yet unknown. Here, we isolated the major bioactive compounds from a hydroethanolic extract of S. aristolochiifolia root by fast centrifugal partition chromatography and evaluated their effects against pancreatic α-amylase and yeast α-glucosidase. A chlorogenic acid-rich fraction (CAF) inhibited α-amylase activity with an IC50 value of 59.28 μg/mL in an uncompetitive manner and α-glucosidase activity with an IC50 value of 9.27 μg/mL in a noncompetitive mode. Also, an astilbin-rich fraction (ABF) inhibited α-glucosidase activity with an IC50 value of 12.30 μg/mL, in a noncompetitive manner. CAF inhibition α-amylase was as active as acarbose while both CAF and ABF were 50-fold more potent inhibitors of α-glucosidase than acarbose. The molecular docking results of chlorogenic acid and astilbin with α-amylase and α-glucosidase enzymes correlated with the inhibition mechanisms suggested by enzymatic assays. Our results prove that S. aristolochiifolia roots contain chlorogenic acid and astilbin, which inhibit carbohydrates-hydrolyzing enzymes, suggesting a new mechanism for the hypoglycemic effect reported for this plant.

Metabolic effects of liraglutide in type 2 diabetic patients.

2018 ◽  
Author(s):  
Mariola Mendez Muros ◽  
Cristobal Morales Portillo ◽  
Antonio Manuel Garrido Hermosilla ◽  
Vianney Magaly Santiago Septimo ◽  
Antonio Perez Perez ◽  
...  
Keyword(s):  
Metabolic Effects ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Metformin: Up to Date

2020 ◽  
Vol 20 (2) ◽  
pp. 172-181 ◽  
Author(s):  
Silvia Sciannimanico ◽  
Franco Grimaldi ◽  
Fabio Vescini ◽  
Giovanni De Pergola ◽  
Massimo Iacoviello ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Current Literature ◽  
Weight Control ◽  
Low Cost ◽  
Hepatic Glucose Production ◽  
Metabolic Effects ◽  
Hypoglycemic Agents ◽  
Positive Effects ◽  
Mesh Terms

Background: Metformin is an oral hypoglycemic agent extensively used as first-line therapy for type 2 diabetes. It improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscles. Metformin improves insulin sensitivity and shows a beneficial effect on weight control. Besides its metabolic positive effects, Metformin has direct effects on inflammation and can have immunomodulatory and antineoplastic properties. Aim: The aim of this narrative review was to summarize the up-to-date evidence from the current literature about the metabolic and non-metabolic effects of Metformin. Methods: We reviewed the current literature dealing with different effects and properties of Metformin and current recommendations about the use of this drug. We identified keywords and MeSH terms in Pubmed and the terms Metformin and type 2 diabetes, type 1 diabetes, pregnancy, heart failure, PCOS, etc, were searched, selecting only significant original articles and review in English, in particular of the last five years. Conclusion: Even if many new effective hypoglycemic agents have been launched in the market in the last few years, Metformin would always keep a place in the treatment of type 2 diabetes and its comorbidities because of its multiple positive effects and low cost.

scholarly journals Metabolic effects of bariatric surgery on patients with type 2 diabetes: a population-based study

2021 ◽  
Author(s):  
Erman O. Akpinar ◽  
Ronald S.L. Liem ◽  
Simon W. Nienhuijs ◽  
Jan Willem M. Greve ◽  
Perla J. Marang-van de Mheen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Bariatric Surgery ◽  
Population Based ◽  
Metabolic Effects ◽  
Population Based Study

scholarly journals First Report ofEurycoma longifoliaJack Root Extract Causing Relaxation of Aortic Rings in Rats

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Bae Huey Tee ◽  
See Ziau Hoe ◽  
Swee Hung Cheah ◽  
Sau Kuen Lam
Keyword(s):  
Erectile Function ◽  
Receptor Activation ◽  
Root Extract ◽  
Ang Ii ◽  
Angiotensin I ◽  
Eurycoma Longifolia ◽  
Vasodilatory Effect

AlthoughEurycoma longifoliahas been studied for erectile function, the blood pressure- (BP-) lowering effect has yet to be verified. Hence, this study aims at investigating the BP-lowering properties of the plant with a view to develop an antihypertensive agent that could also preserve erectile function. Ethanolic root extract was partitioned by hexane, dichloromethane (DCM), ethyl acetate, butanol, and water. The DCM fraction, found to be potent in relaxing phenylephrine- (PE-) precontracted rat aortic rings, was further purified by column chromatography. Subfraction DCM-II, being the most active in relaxing aortae, was studied for effects on the renin-angiotensin and kallikrein-kinin systems in aortic rings. The effect of DCM-II on angiotensin-converting enzyme (ACE) activity was also evaluatedin vitro. Results showed that DCM-II reduced (p<0.05) the contractions evoked by angiotensin I and angiotensin II (Ang II). In PE-precontracted rings treated with DCM-II, the Ang II-induced contraction was attenuated (p<0.05) while bradykinin- (BK-) induced relaxation enhanced (p<0.001).In vitro, DCM-II inhibited (p<0.001) the activity of ACE. These data demonstrate that the vasodilatory effect of DCM-II appears to be mediatedviainhibition of Ang II type 1 receptor and ACE as well as enhancement of Ang II type 2 receptor activation and BK activity.

Orlistat in Obese Patients with Type 2 Diabetes: A Retrospective Assessment of Weight Loss and Metabolic Effects

2004 ◽  
Vol 39 (1) ◽  
pp. 37-42 ◽  
Author(s):  
Edward C. Allie ◽  
Michael P. Kane ◽  
Robert S. Busch ◽  
Gary Bakst ◽  
Robert A. Hamilton
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Metabolic Effects ◽  
Obese Patients ◽  
Retrospective Assessment

scholarly journals “Forever young at the table”: metabolic effects of eating speed in obesity

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Luigi Barrea ◽  
Claudia Vetrani ◽  
Ludovica Verde ◽  
Bruno Napolitano ◽  
Silvia Savastano ◽  
...  
Keyword(s):  
Eating Habits ◽  
Developed Countries ◽  
Metabolic Effects ◽  
Middle Aged ◽  
Anthropometric Parameters ◽  
Cross Sectional ◽  
Cardiometabolic Diseases ◽  
Aged Subjects ◽  
Main Meals

Abstract Background Cardiometabolic diseases (CMD) are recognized as the main causes of morbidity and mortality in developed countries. In recent years eating speed (ES) has been of particular interest since some studies have associated it with the development of obesity and CMD. However, the different impact of the ES at which main meals are eaten on the risk of developing these diseases has not yet been identified. Thus, we aimed to investigate the effect of ES at the main meals (breakfast, lunch, and dinner) on the risk of developing cardiometabolic diseases (type 2 diabetes mellitus, dyslipidaemia and hypertension) in middle-aged Caucasian subjects with obesity. Methods For this purpose we carried out a cross-sectional, observational study. One hundred and eighty-seven middle-aged subjects aged 43.6 ± 16 years were enrolled of which anthropometric parameters and lifestyle habits were studied. A dietary interview was performed to collect information about meal duration and eating habits at the main meals. According to median value of meal duration, meals were classified in two groups: fast eating group (FEG) and slow eating group (SEG). Results The prevalence of dyslipidaemia was more than twice in FEG compared to SEG at lunch and dinner. For all main meals, FEG had a significantly higher risk of dyslipidaemia than SEG (p < 0.05) in unadjusted model. However, when the model was adjusted for age, BMI, physical activity, smoking and alcohol use and medication, the result remained significant for lunch and dinner (p < 0.05). Conclusion The results of our study suggest that fast eating increases at lunch and dinner increase the risk of developing dyslipidaemia in obesity.

Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes

2006 ◽  
Vol 34 (5) ◽  
pp. 798-801 ◽  
Author(s):  
X. Fang ◽  
G. Sweeney
Keyword(s):  
Glucose Production ◽  
Metabolic Effects ◽  
Globular Domain ◽  
Insulin Mimetic ◽  
Receptor Isoforms ◽  
Molecular Events ◽  
Obesity And Diabetes ◽  
Insulin Dependent ◽  
Increased Sensitivity

Nutritional control of molecular events has become of great interest given the increased incidence of diet-induced obesity, and consequently Type 2 (non-insulin-dependent) diabetes, in recent years. The altered adipose tissue content in obese individuals results in an altered profile of circulating adipokines, and here we focus on adiponectin, whose circulating levels decrease in obese individuals. Adiponectin is a 30 kDa protein but circulates primarily as hexameric, oligomeric and, to a lesser extent, trimeric forms. Full-length adiponectin can also be cleaved to produce a fragment containing the globular domain that exerts potent metabolic effects. Adiponectin has insulin-mimetic and -sensitizing actions including stimulation of glucose uptake in skeletal muscle and suppression of glucose production in liver. Hence, adiponectin has attracted great interest as an antidiabetic agent. Adiponectin acts via two receptor isoforms, AdipoR1 (adiponectin receptor 1) and AdipoR2, which have distinct tissue distributions and affinities for recognition of the various adiponectin forms. Expression of AdipoR isoforms can be regulated by hyperinsulinaemia and hyperglycaemia with the consequence of increased sensitivity or resistance to specific forms of adiponectin. In summary, regulation of adiponectin or AdipoR expression may be of great importance in the development of metabolic perturbations characteristic of Type 2 diabetes in obese individuals.

Sign in / Sign up

Export Citation Format

Share Document